EIF2A and chronic myelogenous leukemia, BCR-ABL1 positive: Dudka et al. showed that ISRIB (integrated stress response inhibitor), an inhibitor of PERK-downstream signaling, attenuates ISR by reduction of X-box binding protein 1-mediated RAS (rat sarcoma virus)/RAF (rapidly accelerated fibrosarcoma)/MAPK (mitogen-activated protein kinase)-signaling and eIF2a/ATF4-signaling, which is effective in eradicating CML cells in combination with imatinib [26].